Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease A Novel Liver Disease Biomarker 英文参考文献.docVIP

下载本文档

10
0
约3.1万字
约 7页
2017-05-13 发布于上海
举报
版权申诉

Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease A Novel Liver Disease Biomarker 英文参考文献.doc

1、本文档共7页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease A Novel Liver Disease Biomarker 英文参考文献

SerumDipeptidylPeptidase-4ActivityinInsulin ResistantPatientswithNon-AlcoholicFattyLiver Disease:ANovelLiverDiseaseBiomarker Ga′borFirneisz*,T?′meaVarga,GabriellaLengyel,Ja′nosFehe′r{,Do′raGhyczy,BarnaWichmann,La′szlo′ Selmeci,ZsoltTulassay,Ka′rolyRa′cz,Aniko′ Somogyi DepartmentofMedicine,SemmelweisUniversity,Budapest,Hungary Abstract Background: In a cross-sectional study we studied the fasting serum DPP-4 enzymatic activity (sDPP-4) and the insulin resistanceindex(HOMA2-IR)ingliptinna?¨vepatientswithtype2diabetesandinnon-alcoholicfattyliverdisease(NAFLD) andinhealthycontrols(CNTRL). MethodsandFindings: sDPP-4wasmeasuredbykineticassayin39NAFLD(F/M:19/20,meanage:47.42yrs)and82type2 diabetes(F/M:48/34,62.8yrs)patientsand26(F/M:14/12,35.3yrs)controls.DefinitionofT2Dgroupaspatientswithtype2 diabetesbutwithoutclinicallyobviousliverdiseasecreatednon-overlappingstudygroups.DiagnosisofNAFLDwasbased onultrasonographyandtheexclusionofotheretiololgy.PatientsinT2DandNAFLDgroupsweresimilarlyobese.75gCH OGTTin39NAFLDpatients:24-NGT,4-IGTorIFG(‘‘prediabetes’’),11-type2diabetes.HOMA2-IR:CNTRL:1.44;T2D-group: 2.62(p=0.046vsCNTRL,parametrictests);NAFLD(NGTonly):3.23(p=0.0013vsCNTRL);NAFLD(IFG/IGT/type2diabetes): 3.82(p,0.001vsCNTRL,p=0.049vs2TDgroup).sDPP-4activitywashigherinNAFLDbothwithNGT(mean:33.08U/L)and abnormal glucose metabolism (30.38U/L) than in CNTRL (25.89U/L, p,0.001 and p=0.013) or in T2D groups (23.97U/L, p,0.001andp=0.004).CorrelationsinNAFLDamongsDPP-4andALT:r=0.4637,p=0.0038andcGT:r=0.4991,p=0.0017 andHOMA2-IR:r=0.5295,p=0.0026andamongHOMA2-IRandALT:r=0.4340,p=0.0147andcGT:r=0.4128,p=0.0210. Conclusions: The fasting serum DPP-4 activity was not increased in T2D provided that patients with liver disease were intentionallyexcluded.ThehighserumDPP-4activitiesinNAFLDwerecorrelatedwithlivertestsbutnotwiththefasting plasma glucose or HbA1C supporting that the excess is of hepatic origin and it might contribute to the speedup of metabolicdeterioration.Thecorrelation